Labelled amino acids in plasma of patients with thyrotoxicosis and thyroid cancer after radioiodine treatment.
The levels of total organically bound 131I, per cent of labelled iodoproteins, total labelled iodinated amino acids and a percentage of individual iodinated amino acids (thin-layer chromatography) were measured in serum of 84 patients with thyroid cancer and of 16 patients with thyrotoxicosis at 48 h after the administration of therapeutic dose of 131I. In thyrotoxic patients treated with therapeutic doses of 131I (2 to 39.6mCi; 74 to 1500 MBq) the findings were similar to normal subjects. In patients with thyroid cancer a significant increase of iodotyrosines was found after thyroid radioiodide ablation (100 to 200 mCi; 3.7 to 7.4 GBq). No remarkable differences were found between two groups of patients with thyroid cancer, the first one being treated with thyroid eliminating dose in attempt to activate the metastases of functionally differentiated tumour, while the second one was treated with similar doses (i. e. 100 to 200 mCi) to suppressor destroy a functionally active tumour or its metastases. Even though the hormonogenesis in tumours was hardly distinguishable from the products of its radiation damage, it was suggested that the hormonogenesis in neoplastic tissue differs from that in normal thyroid only quantitatively, being less in patients with thyroid cancer than in these with thyrotoxicosis.
D000596:Amino Acids / Q000097:blood*; D001798:Blood Proteins / Q000032:analysis; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood / Q000532:radiotherapy*; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007553:Isotope Labeling; D011879:Radiotherapy Dosage; D013961:Thyroid Gland / Q000528:radiation effects*; D013963:Thyroid Hormones / Q000097:blood; D013964:Thyroid Neoplasms / Q000097:blood / Q000532:radiotherapy*; D013972:Thyrotropin / Q000097:blood
D000596:Amino Acids; D001798:Blood Proteins; D007457:Iodine Radioisotopes; D013963:Thyroid Hormones; D013972:Thyrotropin